Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.580
+0.010 (0.64%)
Jul 13, 2026, 10:55 AM EDT - Market open
Outlook Therapeutics Revenue
Outlook Therapeutics had revenue of $127.44K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $333.14K. In the fiscal year ending September 30, 2025, Outlook Therapeutics had annual revenue of $1.41M.
Revenue (ttm)
$333.14K
Revenue Growth
n/a
P/S Ratio
569.59
Revenue / Employee
$19,597
Employees
17
Market Cap
190.96M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 1.41M | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | - | - | - |
| Sep 30, 2019 | 8.15M | 5.06M | 163.84% |
| Sep 30, 2018 | 3.09M | -723.96K | -18.99% |
| Sep 30, 2017 | 3.81M | 831.94K | 27.92% |
| Sep 30, 2016 | 2.98M | -2.24M | -42.91% |
| Sep 30, 2015 | 5.22M | -3.83M | -42.33% |
| Sep 30, 2014 | 9.05M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 76.38M |
| Arcturus Therapeutics Holdings | 54.71M |
| Q32 Bio | 53.74M |
| MediWound | 14.48M |
| Caribou Biosciences | 11.20M |
| Alpha Cognition | 10.83M |
| Equillium | 4.39M |
| Humacyte | 2.02M |
OTLK News
- 3 days ago - Outlook Therapeutics Proxy statement: Proxy filing - Filings
- 27 days ago - Outlook Therapeutics resubmits ONS-5010 biologics license application to FDA - TheFly
- 27 days ago - Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics resubmits biologics license application to FDA - TheFly
- 6 weeks ago - Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics Proxy statement: Proxy filing - Filings
- 6 weeks ago - Outlook Therapeutics Proxy statement: Proxy filing - Filings
- 6 weeks ago - Outlook Therapeutics announces pricing of $5M registered direct offering - TheFly